Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol in Aneurysmal Subarachnoid Hemorrhage (CASH)
NCT07144956Phase 3Not yet recruiting
- Sponsor
- Centre Hospitalier Sainte-Anne
- Start
- Dec 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in aneurysmal subarachnoid hemorrhage (SAH) comparing Cilostazol + Nimodipine with Nimodipine + Placebo (2 arms). Primary endpoint: Modified Rankin Scale at 6 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
cilostazol
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT07144956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144956.